Cargando…
Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan
Pertuzumab, a novel anti-human epidermal growth factor receptor 2 (HER2) agent, is effective for metastatic HER2-positive breast cancer when used in combination with taxane and trastuzumab. The aim of the present study was to describe the use of pertuzumab in Japan. A phase I clinical trial of pertu...
Autores principales: | OSAKO, TOMOFUMI, NISHIMURA, REIKI, NISHIYAMA, YASUYUKI, FUJISUE, MAMIKO |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665969/ https://www.ncbi.nlm.nih.gov/pubmed/26807231 http://dx.doi.org/10.3892/mco.2015.640 |
Ejemplares similares
-
Clinical Significance of CK19 Negative Breast Cancer
por: Fujisue, Mamiko, et al.
Publicado: (2012) -
Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study
por: Tashima, Rumiko, et al.
Publicado: (2015) -
The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index
por: Arima, Nobuyuki, et al.
Publicado: (2016) -
Triple Negative Breast Cancer: An Analysis of the Subtypes and the Effects of Menopausal Status on Invasive Breast Cancer
por: Nishimura, Reiki, et al.
Publicado: (2022) -
An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancer
por: Nishimura, Reiki, et al.
Publicado: (2022)